Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA)

Trial Profile

Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PreCePRA
  • Most Recent Events

    • 17 Jun 2017 Interim analysis results (n=50) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 16 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 16 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top